Get the Stockscreener App
27.70
8.69%
2.215
After Hours:
27.60
-0.10
-0.36%
Moderna Inc stock is traded at $27.70, with a volume of 16.43M.
It is up +8.69% in the last 24 hours and up +17.57% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$25.48
Open:
$25.58
24h Volume:
16.43M
Relative Volume:
1.47
Market Cap:
$10.82B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-3.173
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+6.62%
1M Performance:
+17.57%
6M Performance:
+6.05%
1Y Performance:
-35.49%
1-Day Range:
$25.38
$27.75
1-Week Range:
$23.92
$27.75
52-Week Range:
$22.28
$48.92
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
27.70 | 9.96B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Why Is Moderna (MRNA) Stock Rocketing Higher Today - Finviz
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - The Ames Tribune
Moderna (MRNA) Recently Broke Out Above the 20-Day Moving Average - Finviz
Skandinaviska Enskilda Banken AB publ Trims Position in Moderna, Inc. $MRNA - MarketBeat
Norges Bank Buys Shares of 3,439,999 Moderna, Inc. $MRNA - MarketBeat
Former FDA commissioners castigate plan to change vaccine approval standards - Seeking Alpha
Moderna to Present at Upcoming Investor Conferences in March 2024 - ACCESS Newswire
Moderna In Crisis? FDA Memo Ties Vaccines To Deaths, Stock Tumbles! - Smartkarma
Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock? - Finviz
Seasonal Vaccines Market Accelerating Growth and Rising Opportunities Through 2035 - GlobeNewswire Inc.
CapEx per share of Moderna, Inc. – DUS:0QF - TradingView
The FDA’s Leaked Covid Memo Is Reckless and Dangerous - Bloomberg.com
Moderna, Inc. $MRNA Shares Sold by Hsbc Holdings PLC - MarketBeat
Goodwin Advises Moderna With Its $1.5 Billion Five-Year Credit Facility From Ares Management - Mondaq
Moderna (MRNA): Reassessing Valuation After FDA Signals Tougher Vaccine Approval Standards - Yahoo Finance
Officer Klinger Acquires 120 Of Moderna Inc [MRNA] - TradingView
Pres Hoge Acquires 336 Of Moderna Inc [MRNA] - TradingView
MVP: Williams & Connolly's David M. Krinsky - Law360
Transcript : Moderna, Inc. Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-02-2025 11 - MarketScreener
Moderna (MRNA) Responds to FDA Claims Regarding Vaccine Safety - GuruFocus
Prudential Financial Inc. Boosts Stake in Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc.: Dividend historical data and projections - MarketScreener
Is Moderna Stock Underperforming the Nasdaq? - Yahoo Finance
Tougher FDA Rules on Vaccine Approval Might Change the Case for Investing in Moderna (MRNA) - Yahoo Finance
Moderna, Novavax Shares Fall on News FDA Plans to Tighten Vaccine Approvals - The Wall Street Journal
Moderna stock falls after FDA vows to impose new vaccine requirements - The Boston Globe
S&P 500 Gains and Losses Today: Moderna Falls; Synopsys Stock Climbs on Nvidia Partnership - Investopedia
Moderna, Other Pharma Stocks Close Lower After US FDA Reportedly Plans to Toughen Vaccine Approval - marketscreener.com
Moderna Falls As FDA Vows To Impose New Vaccine Rules - MarketScreener
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks - Investopedia
Synopsys, Moderna, Strategy, Q32 Bio, Wolfspeed: Stocks Making The Biggest Moves Today - MSN
Moderna stock slides as FDA moves to tighten vaccine guidelines - Proactive financial news
Top Stock Movers Now: Coinbase, Robinhood, Moderna, Synopsys, and More - Investopedia
Moderna (MRNA) Shares Drop Amid Stricter FDA Vaccine Approval St - GuruFocus
Stock Movers: Moderna, Synopsys, Barrick Mining - Bloomberg.com
Moderna and Novavax Stocks Drop as FDA Outlines Stricter Vaccine Approvals - Barron's
Moderna falls after FDA vows to impose new vaccine requirements - The Detroit News
Moderna, vaccine makers decline following FDA official comments on future approvals (MRNA:NASDAQ) - Seeking Alpha
Moderna Stock Drops as FDA Signals New Restrictions on Vaccine Approvals - Tokenist
Here’s why Moderna is sliding - Traders Union
Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals - Barron's
Moderna Falls as FDA Vows to Impose New Vaccine Requirements - Yahoo Finance
Market movers: Charbone Hydrogen, Moderna, Synopsys... - Proactive financial news
Moderna Falls After FDA Vows to Impose New Vaccine Requirements - Bloomberg.com
Quadrature Capital Ltd Cuts Stake in Moderna, Inc. $MRNA - MarketBeat
Grantham Mayo Van Otterloo & Co. LLC Sells 508,235 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Shares Bought by Charles Schwab Investment Management Inc. - MarketBeat
Moderna (MRNA) Leads Healthcare Gains with 16.19% Surge - GuruFocus
Rhumbline Advisers Acquires 25,390 Shares of Moderna, Inc. $MRNA - MarketBeat
FDA's Prasad Cites Alleged Child COVID Shot Deaths in Push for Stricter Rules - Benzinga
FDA official Prasad says COVID shot deaths mean stricter vaccine approval standards - Seeking Alpha
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):